Ultherapy in Gangnam: why does the shot count vary between clinics?

Ultherapy shot counts, or line counts, differ because plans account for individual variation in regional tissue thickness and target depth.

In clinical use of high-intensity focused ultrasound (HIFU) in Korea, dermal thickness differs across the forehead, eye area, cheeks, and jawline; within one face, thin and thick regions can differ by around 1 mm.

Consequently, one clinic may recommend 800 full-face lines while another recommends 1200 or more.

This makes it easy to become confused about what and how much is included when comparing prices alone.

In consultation, I first explain the target depth and areas before discussing line count.

Shot count, or line count, describes how broadly an area is treated, while output, or energy level, describes how much thermal energy is delivered at a point.

These are separate variables: more lines do not necessarily mean higher energy, and vice versa.

Depth is another important variable; a cartridge for superficial dermis and one reaching the fascial layer target different layers entirely.

In a region with many clinics, such as Gangnam, it is easy to compare only shot counts on price lists. In practice, depth planning and the clinician's ability to reach that depth accurately influence results.

Reports suggest that checking the target layer on real-time ultrasound, such as Ultherapy PRIME's visualization, improves accuracy of target contact compared with relying on feel without imaging.

I therefore recommend checking the following when choosing a clinic.

Ask not only about the total line count, but how many lines are assigned to each depth and area, and whether the clinician uses visualization to check during treatment.

Line count and effect are not simply proportional.

More lines than necessary may crowd thermal coagulation points and increase pain and swelling. Conversely, too few lines for the degree of sagging may not deliver the expected improvement in firmness.

Studies have also reported cases in which patients perceived greater improvement than clinicians assessed.

However, some participants in the same research were judged unchanged or worse, highlighting definite individual variation in effects.

Temporary redness, swelling, bruising, and pain during treatment are most common; most settle naturally within several days.

These reactions may be more pronounced when output is too high or lines overlap excessively in the same area.

Very rare cases of blisters, skin ulcers, and temporary nerve-related reactions have also been reported.

Risk is understood to increase when energy is delivered superficially near bone or when depth is set inappropriately, making real-time confirmation of the target layer important.

I recommend full-face treatment with a sufficient line count for moderate or greater laxity extending to the jawline and neck.

In such cases, I find that addressing both superficial and deep layers tends to produce clearer perceived improvement.

Conversely, for concerns limited to fine lines around the eyes or mouth, or for people with higher body mass and strong skin tension that may limit effects, I believe it is more honest to discuss localized treatment or other approaches rather than force a higher line count.

I acknowledge that more lines can benefit clinic revenue. Nevertheless, my principle is to plan only what is needed after assessing both sagging and tissue thickness.